Evolus reports Q3 EPS (24c), consensus (18c)

Reports Q3 revenue $69M, consensus $67.42M. “Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance and disciplined expense management, create an important transition point for the company, as we continue to expect to achieve profitability1 in the fourth quarter and are positioned for sustainable annual profitability beginning in 2026,” said David Moatazedi, President and Chief Executive Officer of Evolus (EOLS). “Total net revenue of $69.0 million, including $63.2 million in global Jeuveau revenue, represented sequential growth that outperformed typical seasonal trends. In the U.S., we strengthened our market share at 14% year-to-date, underscoring our ability to continue to outperform our competitive set. Importantly, strategic mid-year expense reductions successfully lowered our operating costs, strengthening our financial position in the second half of the year. We also delivered $5.7 million of revenue from Evolysse, increasing revenue above the second quarter run rate after factoring for initial stocking by accounts in the launch quarter, and establishing the brand as the most successful hyaluronic acid filler launch in over a decade. In the fourth quarter, we expect to expand our distribution of Evolysse by broadening our focus to new accounts while driving deeper engagement with our core customers.”